Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Closing Remarks.

Reed1

  • 1Clinical Pharmacology Branch, Medical Ovarian Cancer Section, National Cancer Institute, Bethesda, Maryland, 20892, USA.

The Oncologist
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Dr. Bruce A. Chabner

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case of Chronic Hydrocephalus, in Which the Mental Faculties Remained Unimpaired Till a Short Time before Death.

Edinburgh medical and surgical journal·2018
Same author

Comparison of Argatroban and Hirudin for the Reperfusion of Thrombotic Arterial Occlusion by Tissue Plasminogen Activator.

Journal of thrombosis and thrombolysis·2001
Same author

8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide.

Clinical positron imaging : official journal of the Institute for Clinical P.E.T·2001
Same author

Clinical pharmacology research in the pediatric patient: the challenge continues.

Progress in pediatric cardiology·2000
Same author

Structural changes in the promoter region mediate transvection at the sn-glycerol-3-phosphate dehydrogenase gene of Drosophila melanogaster

Biochemical genetics·2000
Same author

Response

Nature cell biology·2000
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Area of Science:

  • Oncology and Cancer Therapeutics
  • Clinical Pharmacology
  • Medical Research Leadership

Background:

  • Established the Clinical Pharmacology Branch (CPB) at the National Cancer Institute (NCI) to focus on novel cancer drug development and mechanisms.
  • Led the Division of Cancer Treatment (DCT) at NCI, overseeing intramural and extramural research for new cancer therapies.
  • Mentored numerous trainees who became leaders in cancer research and treatment.

Purpose of the Study:

  • To highlight the significant impact of Dr. Bruce A. Chabner's career on cancer treatment and academic medicine.
  • To acknowledge his foundational contributions to drug development, clinical trials, and research leadership.
  • To celebrate his role in advancing cancer chemotherapy and AIDS therapeutics.

Main Methods:

Related Experiment Videos

  • Review of Dr. Chabner's leadership roles at NCI, including founding the CPB and directing the DCT.
  • Compilation of key scientific discoveries and therapeutic advancements made under his guidance.
  • Testimonials from individuals trained or influenced by Dr. Chabner, underscoring his mentorship.

    • Main Results:

    • Discovery of human retroviruses (HTLV-1, HTLV-2) linked to malignancies.
    • Development of adoptive immunotherapy and Paclitaxel (Taxol®) as a major anticancer agent.
    • Development of critical AIDS therapies (AZT, DDI, DDC) and diagnostic tools.
    • Significant contributions to understanding antimetabolite drugs and lymphoma/Hodgkin's disease treatment.
    • Mentorship of numerous successful cancer researchers and clinicians.

    Conclusions:

    • Dr. Chabner's career has profoundly impacted cancer treatment through scientific innovation, strategic leadership, and dedicated mentorship.
    • His work has led to life-saving therapies and advancements across multiple cancer types and AIDS.
    • His ongoing career continues to shape the future of cancer research and patient care.